Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Sales Restructuring Sacrifices Physician Detailing To Payer Marketing

Executive Summary

Merck's restructuring program is shifting selling and marketing resources away from physician detailing towards payer and patient promotion, CEO Richard Clark indicated during the firm's annual business review in Whitehouse Station, N.J

You may also be interested in...



Merck accelerates cuts to U.S. sales force

Merck is cutting 1,200 U.S. sales positions as it transitions to a new commercial model, the company announces May 5. The action is an acceleration of planned efficiencies under its "Plan to Win" cost-savings program, announced in 2005, the firm said (1"The Pink Sheet" Dec. 19, 2005, p. 3). With the most recent lay offs, Merck will have eliminated 1,600 positions, or 20 percent, of its sales force

Merck accelerates cuts to U.S. sales force

Merck is cutting 1,200 U.S. sales positions as it transitions to a new commercial model, the company announces May 5. The action is an acceleration of planned efficiencies under its "Plan to Win" cost-savings program, announced in 2005, the firm said (1"The Pink Sheet" Dec. 19, 2005, p. 3). With the most recent lay offs, Merck will have eliminated 1,600 positions, or 20 percent, of its sales force

Video Kills The Sales Rep? Merck Rolls Out Large Scale Video Detailing

The key to successful video detailing on a large scale is effective market segmentation, Merck President-Global Human Health Peter Loescher said Dec. 12

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS046686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel